Cargando…

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

Radiotherapy has been used for the treatment of cancer for over a century. Throughout this period, the therapeutic benefit of radiotherapy has continuously progressed due to technical developments and increased insight in the biological mechanisms underlying the cellular responses to irradiation. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goedegebuure, Ruben S. A., de Klerk, Leonie K., Bass, Adam J., Derks, Sarah, Thijssen, Victor L. J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339950/ https://www.ncbi.nlm.nih.gov/pubmed/30692993 http://dx.doi.org/10.3389/fimmu.2018.03107

Ejemplares similares

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Yan, Zheng, et al.
Publicado: (2021)

Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
por: Shamshiripour, Parisa, et al.
Publicado: (2022)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma
por: Oladejo, Mariam, et al.
Publicado: (2022)

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors
por: Ji, Xiaoqin, et al.
Publicado: (2023)

The Anti-angiogenic Peptide Anginex Greatly Enhances Galectin-1 Binding Affinity for Glycoproteins
por: Salomonsson, Emma, et al.
Publicado: (2011)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022)

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
por: Shen, Jie, et al.
Publicado: (2023)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
por: de Klerk, Leonie K., et al.
Publicado: (2021)

Editorial: The epidemiologic triads in aquaculture: host, pathogen and environment
por: Chong, Chou Min, et al.
Publicado: (2023)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer
por: Kzhyshkowska, Julia, et al.
Publicado: (2020)

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
por: Bourhis, Morgane, et al.
Publicado: (2021)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
por: Liu, Chenxi, et al.
Publicado: (2022)

Traumatized triad of complementopathy, endotheliopathy, and coagulopathy ˗ Impact on clinical outcomes in severe polytrauma patients
por: Yang, Zhangsheng, et al.
Publicado: (2022)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis In Vitro and In Vivo
por: Lu, Yue, et al.
Publicado: (2021)

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
por: Sato, Mineyoshi, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy
por: van Beijnum, Judy R., et al.
Publicado: (2022)

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
por: Eckert, Franziska, et al.
Publicado: (2018)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment
por: Hanus, Michelle, et al.
Publicado: (2021)

Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies
por: Genard, Géraldine, et al.
Publicado: (2017)

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
por: Yin, Li, et al.
Publicado: (2022)

Cold Tumors: A Therapeutic Challenge for Immunotherapy
por: Bonaventura, Paola, et al.
Publicado: (2019)

Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma
por: Barbhuiya, Mustafa A., et al.
Publicado: (2017)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
por: Qin, Jian, et al.
Publicado: (2023)

Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
por: Adhoute, Xavier, et al.
Publicado: (2022)

Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies
por: Mortara, Lorenzo, et al.
Publicado: (2022)

Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy
por: Zaher, Amira, et al.
Publicado: (2022)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
por: Li, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_brk4cfud8ith9fke1rd40edijl